NexEos Bio

NexEos Bio is a privately held, clinical-stage biotech company targeting eosinophil-driven diseases with a dual-pronged approach of diagnostics and therapeutics. Its lead programs are NTX-1024, a topical ophthalmic therapy for vernal keratoconjunctivitis (VKC), and NDX-3324, a non-invasive imaging agent for diagnosing and managing Eosinophilic Esophagitis (EoE). The company leverages deep scientific expertise in eosinophil biology, with a team that includes pioneers in the field and experienced biopharmaceutical executives. NexEos aims to address significant unmet needs in chronic inflammatory conditions where current diagnostic and treatment options are limited.

Platform targeting eosinophils and their cationic granule proteins for both diagnostic imaging and therapeutic inhibition in inflammatory diseases.

In EoE diagnostics, NexEos competes against the entrenched standard of endoscopic biopsy and may face emerging blood or imaging-based tests. In VKC, competition includes off-label use of immunosuppressants (e.g., cyclosporine) and a developing pipeline of targeted biologics and other novel therapies from larger biopharma companies.